CareDx, Inc.

CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of high value, non-invasive tests to enhance the care and long-term outcomes of transplant recipients. The company has commercialized AlloMap Gene Expression Profile Testing, which aids physicians in surveillance of heart transplant recipients. New data was recently presented at ISHLT 2014 that further supports the clinical utility of AlloMap. CareDx, Inc. also develops new tests for other solid organ transplantation, which are in development.